Omixon And TBG Team Up To Provide HLA Transplant Testing In China

Published: Nov 18, 2016

Omixon, a Budapest molecular diagnostics company, partnered with Taiwan's TBG Biotechnology to distribute and promote Omixon's Holotype HLA products in China, Hong Kong, Taiwan and Australia. Omixon's Holotype HLA genotyping products are used to assess transplantation compatability. TBG and Omixon have optimized Holotype HLA on TBG’s liquid handling DX-A Automation System, and the companies are completing a multi-site customer validation program of the liquid handling system.

Back to news